GD
ALXN

Grandfield & Dodd’s Alexion Pharmaceuticals ALXN Stock Holding History

Grandfield & Dodd’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-7,016
Closed -$1.29M – 213
2021
Q2 		$1.29M Sell
7,016
-356
-5% -$61.1K 0.09% 89
2021
Q1 		$1.13M Sell
7,372
-95
-1% -$14.7K 0.08% 91
2020
Q4 		$1.17M Buy
7,467
+300
+4% +$38.5K 0.09% 89
2020
Q3 		$820K Buy
7,167
+145
+2% +$15.6K 0.07% 101
2020
Q2 		$790K Buy
7,022
+670
+11% +$71.1K 0.08% 104
2020
Q1 		$570K Buy
6,352
+502
+9% +$49.3K 0.07% 109
2019
Q4 		$633K Buy
5,850
+705
+14% +$75.4K 0.06% 118
2019
Q3 		$504K Buy
5,145
+685
+15% +$77.2K 0.05% 130
2019
Q2 		$584K Buy
4,460
+432
+11% +$55.7K 0.06% 121
2019
Q1 		$545K Buy
4,028
+72
+2% +$8.95K 0.06% 125
2018
Q4 		$385K Buy
3,956
+76
+2% +$8.98K 0.05% 132
2018
Q3 		$539K Buy
3,880
+35
+0.9% +$4.39K 0.06% 125
2018
Q2 		$477K Buy
3,845
+30
+0.8% +$3.51K 0.05% 129
2018
Q1 		$425K Sell
3,815
-30
-0.8% -$3.59K 0.05% 138
2017
Q4 		$460K Buy
3,845
+60
+2% +$7.31K 0.05% 141
2017
Q3 		$531K Buy
3,785
+425
+13% +$57.7K 0.06% 127
2017
Q2 		$409K Buy
3,360
+90
+3% +$10.5K 0.05% 144
2017
Q1 		$396K Buy
3,270
+47
+1% +$6.06K 0.05% 141
2016
Q4 		$394K Buy
3,223
+385
+14% +$47.1K 0.05% 140
2016
Q3 		$348K Buy
2,838
+225
+9% +$29K 0.05% 146
2016
Q2 		$305K Buy
2,613
+114
+5% +$16.2K 0.04% 149
2016
Q1 		$348K Buy
2,499
+940
+60% +$138K 0.05% 133
2015
Q4 		$297K Buy
+1,559
New +$272K 0.05% 145
2015
Q3 		– Sell
-1,240
Closed -$224K – 179
2015
Q2 		$224K Hold
1,240
– – 0.03% 161
2015
Q1 		$215K Hold
1,240
– – 0.03% 157
2014
Q4 		$229K Sell
1,240
-9
-0.7% -$1.67K 0.04% 153
2014
Q3 		$207K Buy
+1,249
New +$205K 0.03% 157

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Grandfield & Dodd's ALXN Position: Q3 2021 in Review

Grandfield & Dodd sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 7,016 shares — an estimated $1.29M sold.

Grandfield & Dodd first reported a position in ALXN in Q3 2014 and held it in 27 quarters. The position peaked at $1.29M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Grandfield & Dodd reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Grandfield & Dodd sold 7,016 Alexion Pharmaceuticals shares in Q3 2021, an estimated $1.29M.
  • Grandfield & Dodd first reported a position in Alexion Pharmaceuticals in Q3 2014 and held it in 27 quarters.
  • Grandfield & Dodd's Alexion Pharmaceuticals position peaked at $1.29M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Grandfield & Dodd's 13F filing for Q3 2021, filed 28 Oct 2021.